IMR Press / EJGO / Volume 20 / Issue 1 / pii/1999105

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Case Report

The combination paclitaxel, carboplatin and megestrol acetate is effective in women with recurrent uterine papillary serous adenocarcinoma

Show Less
1 Division of Gynecologic Oncology, University of Vermont, Burlington, Vermont, USA
Eur. J. Gynaecol. Oncol. 1999, 20(1), 18–19;
Published: 10 February 1999
Abstract

Uterine papillary serous adenocarcinoma is an uncommon and very aggressive type of endometrial cancer. A 76-year-old patient diagnosed with recurrent uterine papillary serous adenocarcinoma was prescribed megesterol acetate (160 mg daily), paclitaxel (135 mg/m2) and carboplatin (area under the concentration-time curve of 5) every 4 weeks for 4 courses. She demonstrated complete cli­nical response that was maintained for longer than 6 months with minimal toxicity. The combination megesterol acetate, paclitaxel and carboplatin may be effective in women with recurrent uterine papillary serous adenocarcinoma.

Keywords
Recurrent endometrial cancer
Uterine papillary serous adenocarcinoma
Chemotherapy
Paclitaxel
Carboplatin
Mege-sterol acetate
Share
Back to top